NASDAQ:GLUE Monte Rosa Therapeutics - GLUE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.94 -0.28 (-3.88%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.86▼$7.4250-Day Range$5.95▼$8.2152-Week Range$5.74▼$15.52Volume78,225 shsAverage Volume143,419 shsMarket Capitalization$335.89 millionP/E RatioN/ADividend YieldN/APrice Target$18.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Monte Rosa Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside165.1% Upside$18.40 Price TargetShort InterestBearish5.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.82) to ($2.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector539th out of 988 stocksBiological Products, Except Diagnostic Industry97th out of 162 stocks 3.4 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.40, Monte Rosa Therapeutics has a forecasted upside of 165.1% from its current price of $6.94.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.90% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 2.5 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Monte Rosa Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions83.19% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Monte Rosa Therapeutics (NASDAQ:GLUE) StockMonte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Stock News HeadlinesMarch 16, 2023 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 16, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Morphosys Ag (MOR), Monte Rosa Therapeutics (GLUE)March 21, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 16, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 28, 2023 | seekingalpha.comGLUE Monte Rosa Therapeutics, Inc.February 6, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn SituationFebruary 6, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn SituationFebruary 3, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Upcoming Investor ConferencesMarch 21, 2023 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. January 25, 2023 | finance.yahoo.comHow Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%January 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023November 17, 2022 | finance.yahoo.comAlphabet Inc (GOOGL) Investment Portfolio: Top 15 CompaniesNovember 10, 2022 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business UpdatesNovember 10, 2022 | finance.yahoo.comMonte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business UpdatesNovember 1, 2022 | finance.yahoo.comMonte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven TumorsOctober 20, 2022 | finance.yahoo.comMonte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR SymposiumSeptember 19, 2022 | nasdaq.comMonte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth PlansAugust 30, 2022 | finance.yahoo.comWe're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn RateAugust 11, 2022 | apnews.comMonte Rosa Therapeutics: Q2 Earnings SnapshotJuly 17, 2022 | uk.finance.yahoo.comMonte Rosa Therapeutics, Inc. (GLUE)June 14, 2022 | finance.yahoo.comUpcoming 220K-square-foot South End lab project almost fully leasedMay 17, 2022 | nasdaq.comMonte Rosa Therapeutics vs. Binance Coin: Price Relationship Crosses ThresholdApril 15, 2022 | seekingalpha.comMonte Rosa Therapeutics (GLUE) Investor Presentation - SlideshowApril 8, 2022 | tmcnet.comMonte Rosa Therapeutics Presents Preclinical Data Highlighting PotentialApril 8, 2022 | finance.yahoo.comMonte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022March 29, 2022 | seekingalpha.comMonte Rosa Therapeutics GAAP EPS of -$2.96 misses by $0.43March 29, 2022 | finance.yahoo.comMonte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business UpdatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Company Calendar Last Earnings3/29/2022Today3/20/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.40 High Stock Price Forecast$22.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+165.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.42% Return on Assets-30.46% Debt Debt-to-Equity RatioN/A Current Ratio13.55 Quick Ratio13.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.47 per share Price / Book0.93Miscellaneous Outstanding Shares48,399,000Free Float46,705,000Market Cap$335.89 million OptionableNot Optionable Beta0.96 Key ExecutivesDr. Markus Warmuth M.D. (Age 51)Pres, CEO & Director Comp: $842.99kDr. Owen B. Wallace Ph.D. (Age 53)Chief Scientific Officer Comp: $578.36kDr. Filip Janku M.D. (Age 47)Ph.D., Chief Medical Officer Comp: $511.55kMr. Ajim A. Tamboli C.F.A. (Age 45)Chief Financial Officer Ms. Jennifer ChampouxSr. VP of OperationsDr. Sharon Townson Ph.D. (Age 47)Chief Technology Officer Mr. Phil Nickson J.D. (Age 43)Ph.D., Gen. Counsel Dr. John C. Castle Ph.D. (Age 51)Chief Data Scientist Dr. Jullian G. Jones J.D. (Age 46)M.B.A., Ph.D., Chief Bus. Officer Dr. Silvia Buonamici Ph.D.Sr. VP of Drug Discovery BiologyMore ExecutivesKey CompetitorsVigil NeuroscienceNASDAQ:VIGLCaribou BiosciencesNASDAQ:CRBUSutro BiopharmaNASDAQ:STROSOPHiA GENETICSNASDAQ:SOPHProKidneyNASDAQ:PROKView All CompetitorsInstitutional OwnershipVoya Investment Management LLCSold 6,874 shares on 2/28/2023Ownership: 0.191%Alliancebernstein L.P.Bought 12,400 shares on 2/16/2023Ownership: 0.026%T. Rowe Price Investment Management Inc.Bought 9,761 shares on 2/15/2023Ownership: 3.997%Morgan StanleySold 14,426 shares on 2/15/2023Ownership: 0.223%State of Wisconsin Investment BoardBought 5,117 shares on 2/15/2023Ownership: 0.038%View All Institutional Transactions GLUE Stock - Frequently Asked Questions Should I buy or sell Monte Rosa Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks. What is Monte Rosa Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued twelve-month price targets for Monte Rosa Therapeutics' stock. Their GLUE share price forecasts range from $11.00 to $22.00. On average, they predict the company's stock price to reach $18.40 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts. How have GLUE shares performed in 2023? Monte Rosa Therapeutics' stock was trading at $7.61 at the beginning of the year. Since then, GLUE stock has decreased by 8.8% and is now trading at $6.94. View the best growth stocks for 2023 here. Are investors shorting Monte Rosa Therapeutics? Monte Rosa Therapeutics saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,290,000 shares, a drop of 8.0% from the February 13th total of 2,490,000 shares. Based on an average daily volume of 145,000 shares, the days-to-cover ratio is presently 15.8 days. Currently, 5.9% of the company's stock are short sold. View Monte Rosa Therapeutics' Short Interest. When is Monte Rosa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our GLUE earnings forecast. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Tuesday, March, 29th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.43. What ETFs hold Monte Rosa Therapeutics' stock? ETFs with the largest weight of Monte Rosa Therapeutics (NASDAQ:GLUE) stock in their portfolio include BlackRock Future Health ETF (BMED).Fidelity Growth Opportunities ETF (FGRO). When did Monte Rosa Therapeutics IPO? (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. What is Monte Rosa Therapeutics' stock symbol? Monte Rosa Therapeutics trades on the NASDAQ under the ticker symbol "GLUE." Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include NEA Management Company LLC (15.89%), Avoro Capital Advisors LLC (8.94%), Price T Rowe Associates Inc. MD (7.61%), T. Rowe Price Investment Management Inc. (4.00%), Geode Capital Management LLC (1.16%) and Millennium Management LLC (0.81%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Monte Rosa Therapeutics' stock price today? One share of GLUE stock can currently be purchased for approximately $6.94. How much money does Monte Rosa Therapeutics make? Monte Rosa Therapeutics (NASDAQ:GLUE) has a market capitalization of $335.89 million. The company earns $-73,960,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. How can I contact Monte Rosa Therapeutics? The official website for the company is www.monterosatx.com. The company can be reached via phone at 617-949-2643 or via email at ir@monterosatx.com. This page (NASDAQ:GLUE) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.